Clinical Trial

The Real-world Treatment Satisfaction by Gefapixiant in RCC

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 29, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Chronic cough has a high global prevalence and it is refractory to such treatments by approximately 20% of patients. Gafapixant is a P2X3 receptor antagonist that has demonstrated the reduction of cough in patients with refractory chronic cough(RCC). Taste disturbance is the most frequent adverse event by gefapixant (approximately 60-70%). Although gefapixant is well-tolerated even if taste disturbance has occurred, the impact of taste disturbance on cough-specific QoL remains to be unclear. Therefore, the investigator would like to evaluate factors related to treatment satisfaction by gefapixant in RCC patients. the investigator hypothesize that taste disturbance will be associated with the improvement of cough specific QoL and treatment satisfaction in RCC patients.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-08-05; most recent amendment 2025-01-26.
Status change: Not Yet Recruiting → Recruiting 2025-01-26
Trial Details
NCT Number NCT06542484
Lead Sponsor Nagoya City University
Collaborators: Merck Sharp & Dohme LLC
Conditions Chronic Cough
Enrollment 63 participants
Start Date 2024-12-04
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-29